CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.120
-0.170 (-3.96%)
Apr 28, 2026, 4:00 PM EDT - Market closed

CytomX Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-17.3731.87-0.57-99.32-115.87
Upgrade
Depreciation & Amortization
1.381.772.182.442.71
Upgrade
Asset Writedown & Restructuring Costs
0.40.11-0.25-
Upgrade
Loss (Gain) From Sale of Investments
-2.21-5.31-7.42-0.050.27
Upgrade
Stock-Based Compensation
6.37.678.5613.1313.17
Upgrade
Other Operating Activities
4.484.083.733.413.13
Upgrade
Change in Accounts Receivable
1.090.3332.55-35.20.01
Upgrade
Change in Accounts Payable
0.22-0.3-1.430.07-0.14
Upgrade
Change in Unearned Revenue
-65.6-118.25-89.0116.57-33.95
Upgrade
Change in Other Net Operating Assets
-4.29-8.2-4.63-12.0911.64
Upgrade
Operating Cash Flow
-75.59-86.23-56.04-110.79-119.03
Upgrade
Capital Expenditures
-0.22-0.31-0.84-1.74-1.61
Upgrade
Investment in Securities
-59.52100.01-149.8310024.1
Upgrade
Investing Cash Flow
-59.7499.7-150.6798.2622.49
Upgrade
Issuance of Common Stock
110.457.520.560.65110.21
Upgrade
Other Financing Activities
--29.67--
Upgrade
Financing Cash Flow
110.457.5230.230.65110.21
Upgrade
Net Cash Flow
-24.8920.99-176.48-11.8813.67
Upgrade
Free Cash Flow
-75.81-86.54-56.88-112.53-120.64
Upgrade
Free Cash Flow Margin
-99.48%-62.66%-56.19%-211.67%-323.33%
Upgrade
Free Cash Flow Per Share
-0.55-1.02-0.77-1.71-1.88
Upgrade
Levered Free Cash Flow
-43.21-44.243.66-8.92-46.11
Upgrade
Unlevered Free Cash Flow
-43.21-44.243.66-8.92-46.11
Upgrade
Change in Working Capital
-68.58-126.42-62.51-30.65-22.44
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.